Brief: Yichang Hec Changjiang Pharmaceutical Says QTRLY Operating Revenue Rmb102.4 Mln VS Rmb2.01 Bln
April 29 (Reuters) - YiChang HEC ChangJiang Pharmaceutical
Co Ltd 1558.HK :
* QTRLY OPERATING REVENUE RMB102.4 MILLION VERSUS RMB2.01
BILLION
* Q1 LOSS & TOTAL COMPREHENSIVE EXPENSE ATTRIBUTABLE
ADJUSTED FOR
CONVERTIBLE BONDS RMB132.3 MILLION VERSUS PROFIT OF RMB875
MILLION
Source text for Eikon: ID:nHKS88pRld
Further company coverage: 1558.HK
Recent news on Yichang Hec Changjiang Pharmaceutical Co
See all newsBrief: Yichang Hec Changjiang Pharmaceutical Says Exchange Approved Withdrawal Of Listing Of H Shares
Brief: Yichang Hec Changjiang Pharmaceutical Says Encofosbuvir Tablets (0.3G) Approved For Launch By NMPA
Brief: Yichang HEC Changjiang Pharmaceutical Updates On Filing With Listing Committee
Brief: YiChang HEC Changjiang Pharmaceutical Says Sunshine Lake Pharma To Enter Licensing Agreement
Brief: YiChang HEC Changjiang Pharmaceutical Posts HY Revenue RMB2,454.8 Million